Back HIV Treatment Approved HIV Drugs HIV Mutations Can both Reduce and Enhance Virological Response to Boosted Darunavir (Prezista)

HIV Mutations Can both Reduce and Enhance Virological Response to Boosted Darunavir (Prezista)

Development of viral resistance to anti-HIV drugs is a potential barrier to long-term treatment success. In the current study, published ahead of print in the January 15, 2009 online edition of the Journal of Antimicrobial Chemotherapy, French researchers sought to identify a pattern of HIV protease gene mutations associated with virological response to regimens containing ritonavir-boosted darunavir (Prezista).

The investigators analyzed 153 treatment-experienced patients starting a new salvage regimen that included darunavir/ritonavir as the sole protease inhibitor (PI). At baseline, median HIV RNA level was 4.7 log10 copies/mL and the median CD4 cell count was 142 cells/mm3.

Virological response was defined as an HIV RNA load < 200 copies/mL at month 3. The impact of individual protease gene mutations on virological response to darunavir/ritonavir was evaluated, and the combination of mutations most strongly associated with response was identified.

Results

  • At month 3, 55% of patients had a virological response and the median decrease in viral load from baseline was 1.7 log10 copies/mL.
  • All patients had detectable plasma darunavir concentrations at month 3.
  • Cochran-Armitage procedure identified 8 mutations with a negative impact on virological response, namely K14R, K20I, E34Q, I47V, I54M, K55R, T74P, and I84V.
  • 2 mutations (E35D and V82A), by contrast, had a positive impact on virological response.
  • In multivariate analyses, genotypic resistance scores were highly predictive of virological response at month 3.
  • Other predictors were baseline plasma viral load and use of enfuvirtide (Fuzeon) in enfuvirtide-naive patients.

The study authors wrote, "Among the eight mutations with a negative impact on the virological response, I47V, I54M, T74P and I84V were previously described as darunavir resistance-associated mutations." The others were newly identified.

They also observed that some PI resistance mutations had a positive impact on virological response, indicating that they rendered HIV more susceptible to darunavir/ritonavir.

In conclusion, the researchers stated, "These findings might help to explain the potency of darunavir/ritonavir on PI-resistant HIV."

AP-HP, Groupe hospitalier Bichat-Claude Bernard and Université Denis Diderot-Paris 7, Laboratoire de Virologie, Paris, France; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Service de Virologie, Paris, France; SGS, Aster, S.A.S, Paris, France; AP-HP, Groupe hospitalier Pitié-Salpêtrière, Service de Maladies Infectieuses et Tropicales, Paris, France; AP-HP, Groupe hospitalier Bichat-Claude Bernard and Université Denis Diderot-Paris 7, Service de Maladies Infectieuses et Tropicales, Paris, France.

1/30/09

Reference

D Descamps, S Lambert-Niclot, AG Marcelin, and others. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. Journal of Antimicrobial Chemotherapy. January 15, 2009 [Epub ahead of print]. (Abstract).